Chirag Patel's Stake Rises to 8.4% After Kashiv Acquisition Closes
AMRX sits 96% above its 52-week low of $8.82.
Summary
Amneal co-founder Chirag Patel's beneficial ownership rose to 8.4% after his entities received 6.38 million shares in the Kashiv BioSciences acquisition closing.
Key Events · Ownership and Investor Activity · AMRX
-
Kashiv Acquisition Closes
Amneal completed its acquisition of Kashiv BioSciences on August 10, 2026, paying $375 million in cash and issuing 28,942,098 shares of Class A common stock.
-
Patel's Ownership Increases to 8.4%
Chirag Patel's beneficial ownership rose to 29,097,645 shares (8.4% of class) after his entities CKR and Shivkan received 3,573,771 and 2,807,963 shares respectively.
-
Share Count Expands
Total outstanding Class A shares increased to 377,238,115, reflecting the 28.9 million shares issued for the acquisition.
-
Prior Disclosure Context
The acquisition was approved by shareholders on July 31, 2026, and the share issuance was referenced in the 10-Q filed August 6, 2026.
Analysis · AMRX · Life Sciences
The closing of the Kashiv BioSciences acquisition delivered 6.38 million shares to entities controlled by co-founder Chirag Patel, lifting his beneficial ownership to 29.1 million shares, or 8.4% of the expanded share count. The consideration for the deal was $375 million in cash plus 28.9 million shares, with CKR and Shivkan receiving the allocation. While the transaction had been previously announced and approved by shareholders, this filing confirms the specific distribution to Patel's entities and the resulting ownership stake.
At the time of this filing, AMRX was trading at $17.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $8.82 to $19.26. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.